当前位置: X-MOL 学术Blood Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Peripheral neuropathy in hematologic malignancies - Past, present and future.
Blood Reviews ( IF 7.4 ) Pub Date : 2020-01-17 , DOI: 10.1016/j.blre.2020.100653
Tiffany Li 1 , Hannah C Timmins 1 , Hillard M Lazarus 2 , Susanna B Park 1
Affiliation  

Neurotoxic treatments (including proteasome inhibitors, immunomodulatory drugs and vinca-alkaloids) are often used in the treatment of hematologic malignancy. Peripheral neuropathy can be part of a paraneoplastic syndrome accompanying the disease but more commonly is a consequence of treatment with neurotoxic therapies, and produces sensory, motor, autonomic nerve dysfunction or a combination, leading to pain, loss of sensation and functional disability. This review provides an update on peripheral neuropathy in hematologic malignancy, including risk factors, mechanisms and treatment options. We examine the clinical features and risk factors for peripheral neuropathy following bortezomib, thalidomide, brentuximab vedotin and vinca alkaloid treatment, as well as related compounds. We review the current data on pharmacogenetic risk factors for the development of toxicity and highlight areas of future research.



中文翻译:

血液系统恶性肿瘤的周围神经病变-过去,现在和将来。

神经毒性治疗(包括蛋白酶体抑制剂,免疫调节药物和长春花生物碱)通常用于血液系统恶性肿瘤的治疗。周围神经病变可能是伴随该疾病的副肿瘤综合症的一部分,但更常见的是神经毒性疗法治疗的结果,并产生感觉,运动,自主神经功能障碍或两者结合,导致疼痛,感觉丧失和功能障碍。这篇综述提供了血液系统恶性肿瘤周围神经病变的最新信息,包括危险因素,机制和治疗选择。我们研究了硼替佐米,沙利度胺,布仑妥昔单抗维多汀和长春花生物碱治疗以及相关化合物治疗后周围神经病变的临床特征和危险因素。

更新日期:2020-01-17
down
wechat
bug